Telitacicept plus baricitinib for rheumatoid arthritis that is hard to treat
Observes telitacicept with baricitinib in adults with difficult-to-treat rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
Key facts
- Where
- Hangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07491016, who can take part
Where in China
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhejiang Provincial People's Hospital
- Trial code
- NCT07491016
- Record updated
- 30 March 2026
- Original description
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patientsRead full original descriptionShow less
A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients
Inclusion: 1. Age 18-85 years; 2. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria; 3. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients; 4. Voluntarily provided written informed consent.
Exclusion: 1. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs); 2. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis); 3. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib); 4. Active tuberculosis or active infectious diseases requiring systemic treatment; 6. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due; 7. Other conditions contraindicating participation per investigator judgment; 5. Pregnancy, lactation, or refusal to use contraception during the study; to:Non-adherence or Severe adverse reactions.